The Federal Trade Commission (FTC) is eyeing a tougher approach to its review of pharmaceutical mergers.

The commission said in a statement Tuesday it is launching a working group with domestic and international agencies to identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.

This project will ensure that FTC investigations include fresh approaches that fully analyze and address the varied competitive concerns that these mergers and acquisitions raise, the commission said.

Rebecca Kelly Slaughter, a Democrat designated by President BidenJoe BidenThe Hill’s Morning Report – Presented by Facebook – Split screen: Biden sells stimulus; GOP highlights borderRNC to shadow Biden as he promotes COVID-19 relief billDems’ momentum hits quagmire over infrastructure plansMORE as acting chair of the FTC after he entered office in January, said in Twitter thread the agency needs to revamp its approach to such mergers amid skyrocketing drug prices and ongoing anticompetitive conduct in the pharma industry.

Slaughter added that the commissions approach to pharmaceutical mergers tends to only address overlaps in products and pipeline products between merging parties, but does not capture all of the effects in such mergers.

The @FTC’s longstanding practice in pharma mergers tends to address one important competitive angle: overlaps in products and pipeline products between the merging parties. But I have long been concerned that this approach does not capture all the effects of these deals.

Rebecca Kelly Slaughter (@RKSlaughterFTC) March 16, 2021

She noted that others, including fellow Democratic Commissioner Rohit ChopraRohit ChopraSenate panel advances Biden’s picks to lead SEC, consumer bureauWill the Biden CFPB clamp down on innovation and regulatory sandboxes?Biden reportedly taps top antitrust scholar for FTCMORE and Rep. Katie Porter (D-Calif.), have raised similar concerns.

I have not been alone in my concern; these questions have been raised by many others, including @ChopraFTC and, for example, @katieporteroc. https://t.co/r2TSwAVtRO

Rebecca Kelly Slaughter (@RKSlaughterFTC) March 16, 2021

The FTC will be working with the Justice Departments Antitrust Division and offices of state attorneys general, as well as the Canadian Competition Bureau, the European Commission Directorate General for Competition and the U.K.s Competition and Markets Authority.

Slaughter said in a statement the working group intends to take an aggressive approach to tackling anticompetitive pharmaceutical mergers.

Porter praised the move on Twitter, saying This is a great move from the Biden @FTC that will tackle the same issues I raised in a report earlier this year about how Big Pharma mergers hurt patients and stifle innovation. I stand ready to work with the Administration to hold drug companies accountable.

This is a great move from the Biden @FTC that will tackle the same issues I raised in a report earlier this year about how Big Pharma mergers hurt patients and stifle innovation. I stand ready to work with the Administration to hold drug companies accountable. https://t.co/E7FkFfJv5E

Rep. Katie Porter (@RepKatiePorter) March 16, 2021